| Document |
Document Title |
|
WO/2012/050151A1 |
Provided is a compound or a pharmaceutically acceptable salt thereof represented by general formula (I) which has an excellent blood glucose-lowering effect and protective effect on β cells or the pancreas, and also provided is a pharma...
|
|
WO/2012/050041A1 |
The present invention provides a pest control agent, an acaricide, or a bactericide that contains, as the active ingredient thereof, at least one type of compound selected from aryloxyurea compounds represented by formula (V) (wherein R1...
|
|
WO/2012/040532A1 |
Disclosed are compounds of Formula (I): [PLEASE INSERT CHEMICAL STRUCTURE HERE] or stereoisomers, N-oxides, salts, or prodrugs thereof; wherein: Ring A is phenyl or 5- to 6-membered heteroaryl; (i) R1 and R2 are independently C1-C4 alkyl...
|
|
WO/2012/028582A1 |
Ketosultams and diketopyridines of the formula (I) and the use thereof as herbicides are described. In this formula (I), G, X, Y and Z are each radicals such as hydrogen, and organic radicals such as alkyl. W represents organic radicals ...
|
|
WO/2012/020019A1 |
The present invention encompasses compounds of general formula (I) wherein R11a to R30 and X are defined as in claim 1, which are suitable for the treatment of and/or prevention of chronic inflammatory diseases, autoimmune diseases, skin...
|
|
WO/2012/013728A1 |
The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a...
|
|
WO/2012/012477A1 |
Disclosed are compounds of Formula (I): (I) or stereoisomers, salts, or prodrugs thereof, wherein: (i) R1 and R2 are independently C1-C4 alkyl, or (ii) R1 and R2 together with the carbon atom to which they are attached, form a cyclic gro...
|
|
WO/2012/011081A1 |
The invention relates to compounds of formula (I): in which: n is equal to 0 or 1; D represents an oxygen atom or a bond; W represents a nitrogen atom or a -CH- group; X1 represents a nitrogen atom or a -CH=CH- group; X2 represents an ox...
|
|
WO/2012/008435A1 |
Disclosed is a novel biaryl amide derivative represented by formula (1) and having an affinity for the aldosterone receptor; also disclosed is a pharmaceutically acceptable salt thereof. (In the formula, A is any of the groups represente...
|
|
WO/2012/004287A1 |
The present invention provides compounds of Formula (I), as selective S1 P1 inhibitors, as well as their use for treating multiple sclerosis and other diseases.
|
|
WO/2011/151163A1 |
Process for the preparation of oxadiazoles, useful as intermediates in the preparation of biologically active molecules.
|
|
WO/2011/145669A1 |
Disclosed are the compound represented by formula (I) which is useful as a therapeutic or prophylactic agent for various partial and/or generalized epileptic seizures, or a salt thereof. [In the formula, ring A and ring B independently r...
|
|
WO/2011/132712A1 |
Provided is a novel compound that is useful as a medical drug in that said compound displays strong antimicrobial activity against gram-negative bacteria such as Pseudomonas aeruginosa and drug-resistant strains thereof, on the basis of ...
|
|
WO/2011/131135A1 |
Heteroaryl (alkyl) dithiocarbamate compounds represented by general formula (I) or their pharmaceutical salts, their preparation methods and their uses for preparing antitumor medicines are disclosed, wherein each said substituent is def...
|
|
WO/2011/124087A1 |
Disclosed are acethydrazide derivatives containing oxadiazole-based piperazine represented by the general formula I, geometric isomers thereof as well as pharmaceutically acceptable salts, hydrates or solvates thereof, which belong to th...
|
|
WO/2011/118672A1 |
Disclosed is a pharmaceutical product, particularly a pharmaceutical composition having a plasma kallikrein inhibition activity and is useful as a prophylactic or therapeutic agent for edemas (particularly hereditary vascular edema and c...
|
|
WO/2011/108690A1 |
The disclosed composition containing a compound represented by general formula (I) (refer to the Description for the definitions of the symbols used in the formula), or a salt thereof, has excellent CaSR agonist effects and provides phar...
|
|
WO/2011/108512A1 |
Provided is a novel azomethine oligomer which can ensure sufficient carrier mobility for use as a semiconductor material and which can dissolve in relatively versatile organic solvents, for example, hydrophobic solvents such as toluene, ...
|
|
WO/2011/108724A1 |
An object is to provide a CaSR agonist agent that has excellent CaSR agonist effects, and particularly, a pharmaceutical product that can prevent or remedy diabetes or obesity by the effect of CaSR activation. The aforementioned object i...
|
|
WO/2011/104203A1 |
The present invention provides the compounds of the general formula (I) in which n, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and X are each defined as described below, enantiomers thereof, diastereomers thereof, mixtures thereof and ...
|
|
WO/2011/104671A1 |
The present invention finds application in the field of medicine and, in particular, it regards novel water soluble compounds with furoxan structure capable of inhibiting metabolic pathways involved in the development of the tumours. The...
|
|
WO/2011/104680A1 |
The present invention relates to oxadiazole compounds in all their stereoisomeric and tautomeric forms and mixtures thereof in all ratios; and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceuticall...
|
|
WO/2011/094890A1 |
Provided herein are non-peptide GLP-1 receptor modulator compounds, for example, of Formula (I), pharmaceutical compositions comprising such compounds, and processes of preparation thereof. Also provided are methods of their use for the ...
|
|
WO/2011/092611A1 |
Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, met...
|
|
WO/2011/085406A1 |
Disclosed are muscarinic agonist compounds including oxadiazole derivatives, compositions and preparations thereof. Also disclosed are methods of synthesizing such oxadiazole compounds. Further disclosed are methods for treating a subjec...
|
|
WO/2011/056841A1 |
Embodiments of methods for preparing 3-aminopicric acid from picric acid is described. In one embodiment, the method comprises combining lithium hydroxide, picric acid, and a first solvent to form a first solution, combining lithium hydr...
|
|
WO/2011/046954A1 |
The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseas...
|
|
WO/2011/044307A1 |
This invention is directed to a compound of formula (I): wherein R1, R2 and R3 are as defined herein, a pharmaceutical composition comprising the compound, intermediates and processes for making said compounds, and the use of the compoun...
|
|
WO/2011/043479A1 |
Disclosed is a therapeutic agent for cerebral infarction. Specifically disclosed is a therapeutic agent for cerebral infarction, which comprises an amide derivative represented by general formula (I) [wherein each symbol is as defined in...
|
|
WO/2011/043480A1 |
Disclosed is a homocysteine synthase inhibitor which is useful for the prevention or treatment of diseases associated with a homocysteine synthase. Specifically disclosed is a compound represented by general formula (I) [wherein each sym...
|
|
WO/2011/035874A1 |
The invention relates to N-(1,2,5-oxadiazol-3-yl) benzamides of the general formula (I) as herbicides. In said formula (I), X, Y, Z, and R represent groups such as hydrogen, organic groups such as alkyl, and other groups such as halogen.
|
|
WO/2011/027888A1 |
Disclosed are a diamide-phenyl derivative which inhibits soluble epoxy hydrolase (sEH), and a pharmaceutically acceptable salt of the diamide-phenyl derivative. Specifically disclosed are a compound represented by formula (I), and a phar...
|
|
WO/2011/028651A1 |
Disclosed are inhibitors of human 15 lipoxygenase 1, for example, of formula (I), wherein R1, R2, R3, R4, X, Y, and Z are as defined herein, that are useful in treating a 15-lipoxygenase mediated disease or disorder, e.g., prostate cance...
|
|
WO/2011/016469A1 |
Disclosed is a compound having excellent hypoglycemic action, or a pharmaceutically acceptable salt thereof. Also disclosed is a pharmaceutical composition that has an excellent therapeutic effect and/or prophylactic effect on type 1 dia...
|
|
WO/2011/016470A1 |
Disclosed is a compound having excellent hypoglycemic action, or a pharmaceutically acceptable salt thereof. Also disclosed is a pharmaceutical composition that has an excellent therapeutic effect and/or prophylactic effect on type 1 dia...
|
|
WO/2011/002067A1 |
Disclosed are a heterocyclic derivative which has excellent amyloid β production inhibitory activity, and a use of the heterocyclic derivative. Specifically disclosed is a compound represented by formula (I) or a salt thereof. (In the f...
|
|
WO/2010/151672A2 |
Novel classes of amino acid derived urea compounds and compositions are disclosed. These compounds and compositions are useful in treating, preventing, and/or ameliorating viral infections such as, for example, Hepatitis C Virus.
|
|
WO/2010/148650A1 |
5-membered heteroaryl derivatives of formula (I) or salts thereof, processes for their preparation, pharmaceutical compositions containing them and their uses in the treatment of various disorders mediated by S1P1 receptors are disclosed.
|
|
WO/2010/148649A1 |
5-membered heteroaryl derivatives of formula (I) or salts thereof, processes for their preparation, pharmaceutical compositions containing them and their uses in the treatment of various disorders mediated by S1P1 receptors are disclosed.
|
|
WO/2010/136493A1 |
The present invention provides a compound of formula I' or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, B1, X and n are defined herein. The invention also relates a method for manufacturing the compounds of the inv...
|
|
WO/2010/130063A1 |
The little molecule compound which used for promoting the stem cells hyperplasia and the use thereof. The present compound has great effect for researching the mechanism of stem cells hyperplasia. The present compound and its use for the...
|
|
WO/2010/128156A1 |
A 2,1,3-benzoxadiazole compound as a medicament according to the invention is one of the following compounds: 4-[(4-methoxybenzyl)thio]-7-nitro-2,1,3-benzoxadiazole, 2-[(7-nitro-2,1,3-benzoxadiazol-4- yl)thio]ethyl 4-methoxybenzene-1-sul...
|
|
WO/2010/122968A1 |
Disclosed is a compound useful as an anti-obesity agent. Studies have been made on compounds which have a DGAT1 inhibitory activity and are therefore promising active ingredients for pharmaceutical compositions for treating obesity, type...
|
|
WO/2010/120741A1 |
The present invention relates to compositions and methods for modulating retinol binding to retinol binding protein 4 (RBP4). In particular, the present invention provides compounds having Formula (1) or (2) (Formulae (1), (2)); wherein ...
|
|
WO/2010/115751A2 |
The invention relates to compounds of formula I: wherein R1, R2, Ra, Rb, W, Q and S have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis.
|
|
WO/2010/112461A1 |
The invention relates to compounds of formula (I); wherein R1, R2, Ra, Rb, W, Q and S have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis.
|
|
WO/2010/107984A1 |
The present disclosure provides novel deuterated alpha-(N-sulfonamido)acetamide compounds, their pharmaceutical composition, processes thereof and a method for the treatment of Alzheimer's disease, head trauma, traumatic brain injury, an...
|
|
WO/2010/105179A2 |
The present invention is directed to a compound represented by the following structural formula or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions and method of use of the compounds are also described.
|
|
WO/2010/097372A1 |
The invention relates to the compounds of the general formula (I) wherein n, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and X are defined as described below, to enantiomers thereof, to diastereomers thereof, to mixtures and salts there...
|
|
WO/2010/090304A1 |
Disclosed is an excellent agent for treatment or prevention of dementia, schizophrenia and the like, which has a serotonin 5-HT5A receptor modulating activity. An acylguanidine derivative represented by formula (I), wherein guanidine is ...
|
